Regeneron Pharmaceuticals reported that its experimental monoclonal antibody garetosmab achieved the primary endpoint in a Phase 3 trial for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease characterized by abnormal bone growth. Garetosmab significantly reduced new bone lesions by up to 94%. The company plans to submit for FDA approval by the end of 2025. Concurrently, Regeneron shared positive Phase 2 data on combinations involving GLP-1 receptor agonists and anti-myostatin compounds targeting obesity, reflecting pipeline diversification.